Answer
Grade 1 and 2 injection-site reactions, including erythema, pain and swelling, were reported in 1.2% of patients treated with radium-223 dichloride (Xofigo), compared with 0% receiving placebo.
Sources for this answer
- Xofigo 1100 kBq/mL solution for injectionBayer plc · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked